156 related articles for article (PubMed ID: 22307932)
21. Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors.
Matheeussen V; Lambeir AM; Jungraithmayr W; Gomez N; Mc Entee K; Van der Veken P; Scharpé S; De Meester I
Clin Chim Acta; 2012 Feb; 413(3-4):456-62. PubMed ID: 22093941
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, ADME properties, and pharmacological activities of β-alanyl-D-histidine (D-carnosine) prodrugs with improved bioavailability.
Orioli M; Vistoli G; Regazzoni L; Pedretti A; Lapolla A; Rossoni G; Canevotti R; Gamberoni L; Previtali M; Carini M; Aldini G
ChemMedChem; 2011 Jul; 6(7):1269-82. PubMed ID: 21634010
[TBL] [Abstract][Full Text] [Related]
23. Expression, purification, and characterization of human dipeptidyl peptidase IV/CD26 in Sf9 insect cells.
Dobers J; Zimmermann-Kordmann M; Leddermann M; Schewe T; Reutter W; Fan H
Protein Expr Purif; 2002 Aug; 25(3):527-32. PubMed ID: 12182835
[TBL] [Abstract][Full Text] [Related]
24. Structure-activity relationships for dipeptide prodrugs of acyclovir: implications for prodrug design.
Santos CR; Capela R; Pereira CS; Valente E; Gouveia L; Pannecouque C; De Clercq E; Moreira R; Gomes P
Eur J Med Chem; 2009 Jun; 44(6):2339-46. PubMed ID: 18848738
[TBL] [Abstract][Full Text] [Related]
25. Activity and expression of dipeptidyl peptidase IV on peripheral blood mononuclear cells in patients with early steroid and disease modifying antirheumatic drugs naïve rheumatoid arthritis.
Grujic M; Matic IZ; Crnogorac MD; Velickovic AD; Kolundzija B; Cordero OJ; Juranic Z; Prodanovic S; Zlatanovic M; Babic D; Damjanov N
Clin Chem Lab Med; 2017 Jan; 55(1):73-81. PubMed ID: 27341562
[TBL] [Abstract][Full Text] [Related]
26. Dipeptide derivatives of AZT: synthesis, chemical stability, activation in human plasma, hPEPT1 affinity, and antiviral activity.
Santos C; Morais J; Gouveia L; de Clercq E; Pannecouque C; Nielsen CU; Steffansen B; Moreira R; Gomes P
ChemMedChem; 2008 Jun; 3(6):970-8. PubMed ID: 18389514
[TBL] [Abstract][Full Text] [Related]
27. Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus.
Kobayashi H; Hosono O; Mimori T; Kawasaki H; Dang NH; Tanaka H; Morimoto C
J Rheumatol; 2002 Sep; 29(9):1858-66. PubMed ID: 12233879
[TBL] [Abstract][Full Text] [Related]
28. DPPIV/CD26: a tumor suppressor or a marker of malignancy?
Beckenkamp A; Davies S; Willig JB; Buffon A
Tumour Biol; 2016 Jun; 37(6):7059-73. PubMed ID: 26943912
[TBL] [Abstract][Full Text] [Related]
29. Fluorogenic substrate [Ala-Pro]2-cresyl violet but not Ala-Pro-rhodamine 110 is cleaved specifically by DPPIV activity: a study in living Jurkat cells and CD26/DPPIV-transfected Jurkat cells.
Boonacker E; Elferink S; Bardai A; Fleischer B; Van Noorden CJ
J Histochem Cytochem; 2003 Jul; 51(7):959-68. PubMed ID: 12810846
[TBL] [Abstract][Full Text] [Related]
30. Kinetics of degradation and oil solubility of ester prodrugs of a model dipeptide (Gly-Phe).
Larsen SW; Ankersen M; Larsen C
Eur J Pharm Sci; 2004 Aug; 22(5):399-408. PubMed ID: 15265509
[TBL] [Abstract][Full Text] [Related]
31. Uric acid inhibition of dipeptidyl peptidase IV in vitro is dependent on the intracellular formation of triuret.
Mohandas R; Sautina L; Beem E; Schuler A; Chan WY; Domsic J; McKenna R; Johnson RJ; Segal MS
Exp Cell Res; 2014 Aug; 326(1):136-42. PubMed ID: 24925478
[TBL] [Abstract][Full Text] [Related]
32. A novel prodrug approach for tertiary amines. 3. In vivo evaluation of two N-phosphonooxymethyl prodrugs in rats and dogs.
Krise JP; Charman WN; Charman SA; Stella VJ
J Pharm Sci; 1999 Sep; 88(9):928-32. PubMed ID: 10479356
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors.
Roche D; Greiner J; Aubertin AM; Vierling P
Eur J Med Chem; 2008 Jul; 43(7):1506-18. PubMed ID: 17950955
[TBL] [Abstract][Full Text] [Related]
34. The multifunctional or moonlighting protein CD26/DPPIV.
Boonacker E; Van Noorden CJ
Eur J Cell Biol; 2003 Feb; 82(2):53-73. PubMed ID: 12647932
[TBL] [Abstract][Full Text] [Related]
35. Ala-Pro-cresyl violet, a synthetic fluorogenic substrate for the analysis of kinetic parameters of dipeptidyl peptidase IV (CD26) in individual living rat hepatocytes.
Van Noorden CJ; Boonacker E; Bissell ER; Meijer AJ; van Marle J; Smith RE
Anal Biochem; 1997 Oct; 252(1):71-7. PubMed ID: 9324943
[TBL] [Abstract][Full Text] [Related]
36. Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells.
Duke-Cohan JS; Morimoto C; Rocker JA; Schlossman SF
J Immunol; 1996 Mar; 156(5):1714-21. PubMed ID: 8596018
[TBL] [Abstract][Full Text] [Related]
37. Human serum dipeptidyl peptidase IV (DPPIV) and its unique properties.
Shibuya-Saruta H; Kasahara Y; Hashimoto Y
J Clin Lab Anal; 1996; 10(6):435-40. PubMed ID: 8951616
[TBL] [Abstract][Full Text] [Related]
38. O-N intramolecular acyl migration reaction in the development of prodrugs and the synthesis of difficult sequence-containing bioactive peptides.
Sohma Y; Hayashi Y; Skwarczynski M; Hamada Y; Sasaki M; Kimura T; Kiso Y
Biopolymers; 2004; 76(4):344-56. PubMed ID: 15386265
[TBL] [Abstract][Full Text] [Related]
39. Serum DPPIV activity and CD26 expression on lymphocytes in patients with benign or malignant breast tumors.
Erić-Nikolić A; Matić IZ; Dorđević M; Milovanović Z; Marković I; Džodić R; Inić M; Srdić-Rajić T; Jevrić M; Gavrilović D; Cordero OJ; Juranić ZD
Immunobiology; 2011 Aug; 216(8):942-6. PubMed ID: 21281985
[TBL] [Abstract][Full Text] [Related]
40. Prodrugs of acyclovir--a computational approach.
Karaman R; Dajani KK; Qtait A; Khamis M
Chem Biol Drug Des; 2012 May; 79(5):819-34. PubMed ID: 22260647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
